Literature DB >> 21521024

Role of the XRCC5/XRCC6 dimer in carcinogenesis and pharmacogenomics.

Da-Tian Bau1, Chia-Wen Tsai, Cheng-Nan Wu.   

Abstract

Over the past few decades, the incidence of cancer has rapidly increased all over the world and cancer remains a major threat to public health. It is believed that cancer results from a series of genetic alterations that lead to the progressive disorder of the normal mechanisms controlling cell proliferation, differentiation, death and/or genomic stability. The response of the cell to genetic injury and its ability to maintain genomic stability by means of a variety of DNA repair mechanisms are therefore essential in preventing tumor initiation and progression. From the same viewpoint, the relative role of DNA repair as a biomarker for prognosis, predictor of drug and therapy responses or indeed as a target for novel gene therapy, is very promising. In this article, we have summarized the studies investigating the association between the XRCC5/XRCC6 dimer and the susceptibility to multiple cancers and discuss its role in carcinogenesis and its potential application to anticancer drug discovery.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521024     DOI: 10.2217/pgs.10.209

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  8 in total

1.  Quantitative assessment of the association between XRCC6 C1310G polymorphism and cancer risk.

Authors:  Hong Jiang; Yun Lin; Chang-qing Yang; Qi Li; Jinhong Luo; Ying Zhou; Junli Xue; Wei Wei; Yong Gao
Journal:  Tumour Biol       Date:  2012-12-28

2.  Ku80 cooperates with CBP to promote COX-2 expression and tumor growth.

Authors:  Yao Xiao; Jingshu Wang; Yu Qin; Yang Xuan; Yunlu Jia; Wenxian Hu; Wendan Yu; Meng Dai; Zhenglin Li; Canhui Yi; Shilei Zhao; Mei Li; Sha Du; Wei Cheng; Xiangsheng Xiao; Yiming Chen; Taihua Wu; Songshu Meng; Yuhui Yuan; Quentin Liu; Wenlin Huang; Wei Guo; Shusen Wang; Wuguo Deng
Journal:  Oncotarget       Date:  2015-04-10

3.  The current progress and future prospects of personalized radiogenomic cancer study.

Authors:  Juhn-Cherng Liu; Wu-Chung Shen; Tzu-Ching Shih; Chia-Wen Tsai; Wen-Shin Chang; Der-Yang Cho; Chang-Hai Tsai; Da-Tian Bau
Journal:  Biomedicine (Taipei)       Date:  2015-02-02

4.  The relationship between polymorphisms of XRCC5 genes with astrocytoma prognosis in the Han Chinese population.

Authors:  Xue He; Xikai Zhu; Lei Li; Jiayi Zhang; Ruipeng Wu; Yuan Zhang; Longli Kang; Dongya Yuan; Tianbo Jin
Journal:  Oncotarget       Date:  2016-12-20

5.  Super Secondary Structures of Proteins with Post-Translational Modifications in Colon Cancer.

Authors:  Dmitry Tikhonov; Liudmila Kulikova; Arthur Kopylov; Kristina Malsagova; Alexander Stepanov; Vladimir Rudnev; Anna Kaysheva
Journal:  Molecules       Date:  2020-07-09       Impact factor: 4.411

6.  Evaluation of X-Ray Repair Cross-Complementing Family Members as Potential Biomarkers for Predicting Progression and Prognosis in Hepatocellular Carcinoma.

Authors:  Jie Mei; Huiyu Wang; Runjie Wang; Jiadong Pan; Chaoying Liu; Juanying Xu
Journal:  Biomed Res Int       Date:  2020-03-17       Impact factor: 3.411

7.  Bioinformatics analysis identifies potential biomarkers involved in the metastasis of locoregionally advanced nasopharyngeal carcinoma.

Authors:  Rongrong Hu; Xujun Xu; Lujiao Mo; Mengjie Chen; Yuxiang Liu
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

8.  The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.

Authors:  Zheng-Yan Zhang; Shi-Long Zhang; Hui-Ling Chen; Yu-Qin Mao; Zhan-Ming Li; Chao-Yue Kong; Bing Han; Jin Zhang; Yong-Hui Chen; Wei Xue; Wei Zhai; Li-Shun Wang
Journal:  Cell Prolif       Date:  2020-06-14       Impact factor: 6.831

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.